Insight · September 13, 2026
After the Summary Statement: Resubmit, Redirect, or Stop
Reviewed by Noradelis Scientific Leadership
Life-science PhD · NIH-funded PI · U.S. and European grant-review experience
An unsuccessful application leaves two questions: what prevented funding, and whether another attempt is justified. The summary statement helps answer the first. The second also requires an assessment of cost, scientific fit, timing, and the company's remaining resources.
What the document contains
NIH summary statements provide assigned reviewers' written critiques and applicable criterion scores. For discussed applications, they also include the overall impact score and a summary of the panel discussion. Applications that are not discussed do not receive an overall impact score or a discussion summary, but written critiques remain available.
A discussion summary records the panel's deliberation. Critiques for a not-discussed application do not provide that collective account. Disagreements between reviewers may therefore remain unresolved. This distinction changes the information available; it does not make a not-discussed result benign.
Whether a percentile appears should be checked on the actual statement rather than assumed. NINDS review guidance.
Read the reasons alongside the scores
The overall impact score is not an arithmetic average of criterion scores. Both score level and disagreement among reviewers can help identify concerns, but neither substitutes for reading the critiques.
A divided assessment may reflect ambiguity, differences in expertise, or a substantive dispute. It does not by itself predict a better resubmission outcome. Likewise, an unfavorable Approach or Significance score does not establish whether the underlying problem is presentation or science.
| Concern | Question to resolve | Possible response |
|---|---|---|
| Presentation | Was necessary evidence present but unclear or difficult to locate? | Clarify the argument and organization |
| Research plan | Are milestones, dependencies, controls, or feasibility inadequate? | Restructure the plan; obtain additional evidence where necessary |
| Scientific premise | Does the criticism challenge the central assumption or the value of the proposed work? | Reassess the premise before committing to another submission |
These categories can overlap. A revision should address the concern that materially affects the project's credibility, not simply the easiest comment to answer.
Three responses
Resubmit when the central project remains credible and the important concerns can be addressed within an acceptable cost and schedule. NIH generally permits one A1 resubmission within 37 months of the original application. It includes an Introduction responding to the previous review; confirm the applicable instructions and page limit.
Redirect when the science remains viable but another institute or opportunity offers a better scientific or programmatic fit. Discuss the proposed direction with the program officer. Institute assignment and review-panel assignment are separate matters; a different institute does not guarantee different reviewers or a higher score.
Stop or defer when resolving the central concern would require resources the company cannot justify, the opportunity is poorly aligned, or another project offers a stronger use of the available time. A decision to stop an application is not necessarily a decision to abandon the technology.
Before choosing, discuss the summary statement, proposed changes, and funding context with the program officer. Prepare specific questions rather than asking only whether the score is fundable.
Application limits affect sequencing
HHS accepts up to nine covered new and resubmission Phase I, Fast Track, and Direct Phase II applications or proposals per company per fiscal year. The limit spans HHS components.
Separately, NIH's PI policy limits specified new, renewal, resubmission, and revision applications to six across council rounds in a calendar year, with exceptions for T activity codes and R13 applications. Fiscal-year and council-year counting differ; neither limit can be assumed to bind first in every case. HHS company limit · NIH PI limit.
A resubmission consumes time and may count against these limits. The aggregate success-rate table does not provide a new-versus-resubmission comparison, so it cannot justify a general promise that an A1 will fare better.
Implications
The useful output of a summary-statement review is a decision and a defined revision plan. Identify the material concern, establish what resolving it would require, and compare that commitment with the company's alternatives. Resubmission is appropriate when that assessment supports it, not simply because an A1 is available.
Related: Anatomy of an NIH SBIR/STTR Application · The Strategic Value of SBIR Funding.
Need help with your next funding decision? Explore summary-statement and resubmission strategy.